Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC)

详细信息    查看全文

• 作者：Massimiliano Berretta ; Ernesto Zanet ; Guglielmo Nasti ; Arben Lleshi ; Sergio Frustaci ; Francesco Fiorica ; Aless ; ra Bearz ; Renato Talamini ; Chiara Lestuzzi ; Renzo Lazzarini ; Rossella Fisichella ; Renato Cannizzaro ; Rosario Vincenzo Iaffaioli ; Salvatore Berretta ; Umberto Tirelli
• 关键词：Colorectal cancer ; Cancer therapy in elderly ; Metastatic cancer ; Oxaliplatin
• 刊名：Archives of Gerontology and Geriatrics
• 出版年：2012
• 出版时间：September-October, 2012
• 年：2012
• 卷：55
• 期：2
• 页码：271-275
• 全文大小：240 K

文摘

Elderly patients constitute a subpopulation with special clinical features that differ from those of the general population and are under-represented in clinical trials. We retrospectively analyzed the toxicity and efficacy of oxaliplatin-based chemotherapy in the treatment of elderly patients affected by metastatic (m) CRC. Seventy-five consecutive patients aged 65-75 years (median age 71 years), 51 males and 24 females, with mCRC and measurable disease, were analyzed. The primary site of metastases was the liver (38.6 % of patients). The majority of patients had a performance status (PS) according to the Eastern Cooperative Oncology Group (ECOG) PS before treatment of 0-1 (96 % ). The overall response rate was 57.3 % , median progression-free survival was 7 months and median overall survival was 27 months. The main hematological and extra-hematological toxicities (grade 3 or 4) were neutropenia (20.0 % ), and neurological toxicity or diarrhea (6.7 % ), respectively. No toxic death occurred. Oxaliplatin-based chemotherapy maintains its efficacy, and safety in elderly patients with mCRC and good PS. This regimen should be considered in the treatment of this particular setting of patients.